Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from MindWalk Holdings ( (HYFT) ).
On December 15, 2025, MindWalk Holdings reported record financial growth for the second quarter of fiscal 2026, with a 54% increase in revenue and a 94% rise in gross profit year-over-year. The company also announced strategic advancements in its AI asset pipeline, including progress in its GLP1 receptor agonist program and a universal dengue vaccine initiative. MindWalk completed a corporate rebranding, expanded its leadership team, and divested its Netherlands operations to focus on its core BioNative AI initiatives. Additionally, the company is forming a Cayman Islands corporation to house segregated portfolios for its AI-driven programs, allowing direct investor participation. These developments are expected to enhance MindWalk’s industry positioning and operational capabilities.
The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.
Spark’s Take on HYFT Stock
According to Spark, TipRanks’ AI Analyst, HYFT is a Neutral.
MindWalk Holdings’ overall stock score is primarily impacted by its financial performance, which is currently weak due to declining revenues and significant losses. The technical analysis provides some support with moderate bullish indicators, while the earnings call offers a positive outlook with record revenue growth and strategic advancements. However, the negative P/E ratio and lack of dividend yield weigh down the valuation score.
To see Spark’s full report on HYFT stock, click here.
More about MindWalk Holdings
MindWalk Holdings is a BioNative AI biotherapeutic research and technology company that combines in silico and wet lab operations for biologics discovery and development. The company operates a proprietary BioNative AI platform built on patented HYFT® patterns, which underpin its LensAI software platform. This platform harmonizes and analyzes diverse biological data to deliver actionable insights, supporting rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics.
Average Trading Volume: 561,592
Technical Sentiment Signal: Hold
Current Market Cap: $81.7M
Find detailed analytics on HYFT stock on TipRanks’ Stock Analysis page.